Comparing ivonescimab with standard PD-1 drugs before surgery for non-small cell lung cancer
Compares ivonescimab with PD-1 inhibitors given before surgery in non-small cell lung cancer.
Key facts
- Who runs it
- Peking University People's Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 30 Oct 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Ivonescimab
- PD-1 Inhibitors
- Record updated
- 3 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with non-small cell lung cancer, stage IB-IIIB, who need surgery to remove the cancer after treatment before surgery.
- Sex
- All sexes can join.
- Disease stage
- Non-small cell lung cancer, stage IB-IIIB, that needs radical surgery after treatment before surgery.
Main reasons for not taking part
- Another type of cancer, including cancer in another organ
- Advanced cancer that cannot be removed (stage IV or stage IIIC)
- Pregnancy or breastfeeding
- Severe organ problems, such as heart or kidney failure
- Tissue sample of insufficient quality
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients with non-small cell lung cancer (Stage IB-IIIB) who require radical surgery following neoadjuvant therapy
Who cannot take part
- Histology of other malignant tumors, including concurrent malignant tumors of other organ systems
- Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC)
- Severe organ dysfunction (e.g. cardiac or renal insufficiency)
- Pregnancy or lactation
- Insufficient sample quality
- Other judgments by the Investigator that the patient should not participate in the study
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Fan Yang, MD.Taking people
About the trial
What the trial wants to find out
This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1/VEGF bispecific antibody, with those of conventional PD-1 inhibitors. Beyond evaluating its direct therapeutic benefits, this research also seeks to elucidate the potential mechanisms underlying the enhanced efficacy of Ivonescimab. Additionally, the study will conduct secondary exploratory analyses, including the identification and validation of predictive and prognostic biomarkers, as well as multi-omics profiling to investigate the molecular mechanisms of action. Collectively, these efforts aim to provide comprehensive experimental data to support the rational clinical application of Ivonescimab and the development of precision medicine strategies for NSCLC.
The 2 groups in the trial
- Ivonescimab neoadjuvant therapy group
Patients in this group will receive ivonescimab as neoadjuvant therapy
Treatment: Ivonescimab
- PD-1 inhibitors neoadjuvant therapy group
Patients in this group will receive other PD-1 inhibitors as neoadjuvant therapy
Treatment: PD-1 Inhibitors
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Plain-language title
- Comparing ivonescimab with standard PD-1 drugs before surgery for non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 June 2026